NCT06451796

Brief Summary

Hypothesis: Treatment with the hydrophilic coated valved intraurethral catheter up to 16 hours per day is effective, well tolerated and seemingly safe for treatment of women with stress incontinence. Test persons: Ten to twenty stress incontinent women. Treatment time: Up to two weeks

Trial Health

57
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
20

participants targeted

Target at below P25 for all trials

Timeline
Completed

Started Jun 2024

Shorter than P25 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

May 28, 2024

Completed
14 days until next milestone

First Posted

Study publicly available on registry

June 11, 2024

Completed
7 days until next milestone

Study Start

First participant enrolled

June 18, 2024

Completed
3 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2024

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2024

Completed
Last Updated

June 21, 2024

Status Verified

June 1, 2024

Enrollment Period

3 months

First QC Date

May 28, 2024

Last Update Submit

June 19, 2024

Conditions

Keywords

Female Stress Incontinence

Outcome Measures

Primary Outcomes (1)

  • Safety primary: Migration of device to bladder

    Number of Participants with Migration of device to bladder

    2 weeks

Secondary Outcomes (8)

  • Safety secondary: Culture confirmed urinary tract infections.

    2 weeks

  • Safety secondary:Need for antibiotics.

    2 weeks

  • Safety secondary: Discomfort at self-catheterization.

    2 weeks

  • Safety secondary: Difficulties emptying the bladder.

    2 weeks

  • Safety secondary: Discomfort at catheter removal.

    2 weeks

  • +3 more secondary outcomes

Other Outcomes (1)

  • Functionality: Is long term continuous use acceptable?

    2 weeks

Interventions

ObtinuDEVICE

Treatment of Female Stress Incontinence with a hydrophilic coated valved intraurethral catheter

Eligibility Criteria

Age18 Years - 75 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Adult women suffering from stress urinary incontinence

You may qualify if:

  • Willing to participate
  • Adult, competent woman who understands Danish.
  • SUI as dominant symptom; daily or almost daily.
  • Residual urine \< 150 ml.
  • POP-Q prolapse ≤ grade 2.
  • Negative urine stix/Urine D+R.
  • Min. 2 months local vaginal estrogen treatment if the woman is postmenopausal.
  • Mobile and self-reliant woman.
  • Motivated.

You may not qualify if:

  • Allergy to the silicone material
  • Pregnancy or breastfeeding
  • Unexplained hematuria.
  • Current inflammatory disorders
  • Malignant disorders of the urethra.
  • Urethral stricture
  • Visual diverticulum.
  • AK treatment.
  • Prosthetic heart valve surgery.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

GynCare

Herlev, DK, 2730, Denmark

RECRUITING

Study Officials

  • Pia Sander, MD PhD

    Herlev Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Dorthe Snejbjerg, MD Phd

CONTACT

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
UNKNOWN
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 28, 2024

First Posted

June 11, 2024

Study Start

June 18, 2024

Primary Completion

September 1, 2024

Study Completion

September 1, 2024

Last Updated

June 21, 2024

Record last verified: 2024-06

Data Sharing

IPD Sharing
Will not share

Locations